SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Oak Tree who wrote (1672)9/20/2001 10:28:55 PM
From: John Metcalf  Read Replies (2) | Respond to of 2515
 
>All that has been shown to date is that C225 is not very toxic -- and that in studies with complicated design -- that it may make some chemotherapy work better for some patients.>

That's what is available in public. Do you suppose that Bristol-Myers may have access to more information?



To: Oak Tree who wrote (1672)9/21/2001 8:35:16 AM
From: telephonics  Read Replies (1) | Respond to of 2515
 
The response by the Oncologists,Hemotologists and the cancer research community in general have been overwhelmingly positive to the data released via professional society conventions. The next such will take place in Europe and I expect to see the same enthusiastic interest from the professionals.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News